U.S. halts usage of Johnson & Johnson coronavirus vaccine over rare blood clots

U.S. federal health agencies on Tuesday recommended pausing use of Johnson & Johnson’s COVID-19 vaccine for at least a few days after six women under age 50 developed rare blood clots after receiving the shot, dealing a fresh setback to efforts to tackle the pandemic. Johnson & Johnson said it would delay rollout of the… Read More U.S. halts usage of Johnson & Johnson coronavirus vaccine over rare blood clots

South Africa signs deal to secure Johnson & Johnson coronavirus vaccine

South Africa has signed an agreement with Johnson & Johnson to secure 11 million COVID-19 vaccine doses and will ease restrictions due to a decline in new cases, President Cyril Ramaphosa said on Sunday. South Africa has been the hardest-hit on the continent by the pandemic, recording almost half of the COVID-19 deaths and more… Read More South Africa signs deal to secure Johnson & Johnson coronavirus vaccine

U.S. CDC panel approves Johnson & Johnson coronavirus vaccine

A U.S. Centers for Disease Control and Prevention advisory panel voted unanimously on Sunday to recommend Johnson & Johnson’s COVID-19 shot for widespread use, and U.S. officials said initial shipments would start on Sunday. Providing a final clearance for the vaccine a day after it was authorized by U.S. regulators, the Advisory Committee on Immunization… Read More U.S. CDC panel approves Johnson & Johnson coronavirus vaccine

New York files charges against Johnson & Johnson on insurance fraud regarding opioid claims

New York state filed civil charges on Thursday accusing Johnson & Johnson of insurance fraud for downplaying the risks of opioid painkillers, including to doctors and elderly patients. J&J and its Janssen Pharmaceuticals affiliate were accused of targeting elderly patients for opioid treatment despite the risks of side effects such as falls, fractures and neuropsychiatric… Read More New York files charges against Johnson & Johnson on insurance fraud regarding opioid claims

Johnson & Johnson set to acquire Momenta Pharmaceuticals in $6.5billion deal

Johnson & Johnson said on Wednesday it would buy Momenta Pharmaceuticals Inc for about $6.5 billion in cash to bolster its portfolio of treatments for autoimmune diseases. Momenta shares were up 68% at $51.98 before the bell, just shy of the offer price of $52.20. The deal gives Johnson & Johnson’s Janssen unit access to… Read More Johnson & Johnson set to acquire Momenta Pharmaceuticals in $6.5billion deal

Oklahoma judge orders Johnson & Johnson to pay $572million in opioid epidemic case

An Oklahoma judge on Monday ordered Johnson & Johnson to pay $572.1 million to the state for its part in fueling an opioid epidemic by deceptively marketing addictive painkillers. J&J said it would to appeal the decision, though the award was below what some investors and analysts had feared, in what had been a $17… Read More Oklahoma judge orders Johnson & Johnson to pay $572million in opioid epidemic case